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Abstract
Avirus-dependent fusion assay was utilized to examine the activity of a panel of HIV-1, -2, and SIV isolates of distinct coreceptor phenotypes.
This assay allowed identification of entry inhibitors, and characterization of an antagonist of a Rac guanine nucleotide exchange factor, as an
inhibitor of HIV-mediated fusion.
© 2007 Elsevier Inc. All rights reserved.Keywords: HIV-1; Envelope; Rac; FusionHIV infection is initiated by binding of envelope surface
protein (SU or gp120) to CD4 and coreceptor, usually either
chemokine receptor, CCR5 or CXCR4 (Pierson and Doms,
2003). This results in conformational changes in transmem-
brane envelope protein (TM or gp41), resulting in insertion of
the fusion peptide into the cell membrane, and subsequent
fusion of viral and cell membranes. HIV envelope acts as a
chemokine mimic, stimulating responses such as chemotaxis,
gene transcription, and phosphorylation (Sodhi et al., 2004).
One target of this signaling pathway is the actin filament
network (Matarrese and Malorni, 2005). Reorganization of the
actin cytoskeleton is a critical feature of HIV-induced fusion
(Pontow et al., 2004). This is mediated by activation of Rho family
GTPases, especially Rac (Burridge and Wennerberg, 2004). Rac
regulates diverse cellular processes, including intercellular adhe-
sion, cytoskeletal membrane ruffling and lamellipodia formation,
proliferation, and gene transcription. The active, GTP-bound form
of Rac is negatively regulated by Rac GTPases (GAPs) and
positively regulated by Rac guanine nucleotide exchange factors
(GEFs). Tiam1 is a GEF specific for Rac, while others are more
promiscuous in activating multiple Rho GTPases.
In order to further elucidate the role of Rac activation in HIV
fusion, we made use of a novel virus-dependent fusion assay⁎ Corresponding author. Fax: +1 314 747 2120.
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doi:10.1016/j.virol.2007.06.022(Clavel and Charneau, 1994; Esser et al., 1999; Murakami et al.,
2004; Pontow et al., 2004). This is based on the ability of virus
particles to bridge at least two cells and allow transfer of
cytoplasmic contents. In this assay, we use U87 glioma cells
expressing CD4 and CCR5 or CXCR4, as well as vaccinia virus
expressing T7 polymerase. The second population of U87 glioma
cells, with CD4 and CCR5 or CXCR4, is infected with a vaccinia
virus with a β-galactosidase gene under the regulation of the T7
promoter. A three-hour incubation of these two cell populations in
the presence of fusion-competent virus particles allows fusion,
quantified byβ-galactosidase activity. Sensitivity of the assaywas
found to be enhanced by serum starvation for 24–48 h prior to
fusion. We show here that this assay is rapid, flexible, and
applicable to a wide range of lentivirus isolates. Moreover, this
assay is useful for examining the activity of inhibitors of receptor
or coreceptor binding, fusion peptide activity, as well as
subsequent fusion activities, including Rac activation.
Results
Comparison of virus-dependent fusion and infection assays
and the env-dependent fusion assay
The virus-dependent fusion assay was directly compared to
the env-dependent fusion assay (Fig. 1). For the env-dependent
fusion assay, a macrophage-tropic virus, derived from the YU2
Fig. 1. Comparison of Env-dependent and virus-dependent fusion assays, using
an Env packaging-defective mutant proviral clone (L12E). Virus particles from
HIV-1 MA mutant L12E have diminished levels of envelope incorporation and
demonstrate little virus-dependent fusion activity. In contrast, transfection of
these proviral clones into BSC40 cells results in similar levels of Env-induced
fusion when cells are mixed with U87-CD4 cells.
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resulting in substitution of L12E within the MA protein,
resulting in a defect in envelope incorporation in virus particles
(Freed and Martin, 1996; Kaushik and Ratner, 2004). Both
proviral clones expressed similar amount of cell-surfaceFig. 2. Virus-dependent fusion assay results are comparable to levels of infection
of HeLa.CD4.CCR5 cells containing an LTR-lacz reporter using viruses with
Env V3 mutations. These viruses include amino acid substitutions in the V3
envelope domain that affect their efficiency of use of CCR5 (Hung et al., 1999).envelope, as demonstrated by the fusion assay (Fig. 1, left-
hand bars). However, in the virus-dependent fusion assay, the
WT virus is capable of inducing fusion, whereas the L12E virus,
defective in envelope incorporation, fails to induce fusion
activity in this assay (Fig. 1, right-hand bars).
The virus-dependent fusion and infection assays were also
compared with isogenic viruses that differed only in the
sequence of their V3 envelope domain (Fig. 2) (Hung et al.,
1999). Virus p2027 includes the V3 loop from the R5 strain
SF162. In contrast, virus IDI has a V3 loop derived from X4
strain HXB2, with the exception of substitutions at positions 27,
29, and 30 of the V3 loop that are found in SF162. Virus EIDI is
identical to virus IDI with the exception of an additional
substitution at position 25. Twenty or fifty nanograms of virus
was tested in the virus-dependent fusion assay, as described
above. In contrast, 10 or 50 ng of virus was tested for infection
of Magi.CD4.CCR5 cells (Pirounaki et al., 2000). The viruses
exhibited dose-dependent levels of infection and fusion in these
assays, and the results were quite similar.
The virus-dependent fusion and infection assays were also
tested with a panel of 40 primary HIV isolates with differences in
coreceptor tropism, as well as viruses derived from 14 HIV-1
molecular clones, 2 HIV-2 molecular clones, and 2 SIV
molecular clones (Table 1, Fig. 3). For this purpose, fusion
assays were performed with U87.CD4.CCR5 and U87.CD4.
CXCR4 cells, whereas infection assays were performed with
Magi.CD4 or Magi.CD4.CCR5 cells (which also express
CXCR4). In each case, the virus-dependent fusion and infection
assays gave comparable results, demonstrating the utility of this
assay to screen a wide variety of laboratory and primary isolates.Table 1
Panel of isolates tested with virus-dependent fusion assay and Magi assay
Virus or panel Coreceptor usage Novel properties
Primary isolates
BaL, SF162 R5
LAI, 8 primary isolates X4 Isolates from diverse clades
from NIH AIDS Repository
89.6, MN R5 X4
Sequential Isolates R5→X4 27 longitudinal isolates
from 6 HIV-infected
MACS subjects
Molecular clones
ADA, BaL, SF162,
YU2 (V3 mutant
HXB2 chimeras)
Variable R5 Env chimeras and mutants
that express V3 loop or
minimal sequence
determinants for CCR5
usage in HXB2 backbone
HXB2 X4
HIV-2 (ES, ROD10) R5 X4
SIV (mne, pbj) R5 X4
Luciferase reporters
ADA, SF162,
YU2 chimeras R5
Multiple mutants with
minimal sequence
determinants for R5 use
HXB2 X4
SF2, 89.6 R5 X4
Fig. 3. Virus-dependent fusion assay and infection results with HIV-2 and
SIVmne. Different amounts of virus produced from infectious molecular clones
by transfection of 293T cells were used in fusion assays with U87.CD4.CCR5
cells or infection assays with Magi.CD4.CCR5 cells.
Fig. 4. Inhibition of virus-dependent fusion with antibodies or peptide inhibitors.
(a) Antibody neutralization studies were performed with anti-CCR5 antibody
2D7 or anti-CD4 antibody Sim2. Virus-dependent fusion assays (top) are
compared to infection assays performed for 24 h with U87.CD4.CCR5 cells
(bottom). (b) Dose-dependent inhibition of virus-dependent fusion with T-20
was examined. Two different sources of T-20 were obtained from the NIH AIDS
Research and Reference Repository, derived originally from DAIDS (with free
N and C-terminal amino acids) and Trimeris (N-acetylated derivative). RLU,
relative light units.
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inhibitors
The virus-dependent fusion and infection assays were
compared in studies of entry inhibitors that specifically block
SU-mediated CD4 binding (Sim2) or CCR5 binding (2D7) or
TM-mediated fusion (T20, Fig. 4). U87.CD4.CCR5 cells were
pre-incubated with antibody or drug, at the indicated concen-
trations for 12 h. For fusion assays, the cells were also infected
with either vaccinia viruses expressing β-galactosidase or T7
polymerase, as described above. The cells were then exposed to
100 ng of HIV-luc virus (YU2-derived), for either 3 h for the
fusion assay or 24 h for the infection assay (Pontow and Ratner,
2001). Fusion activity was determined by β-galactosidase
activity, as described above. Infectious virus was quantified by
luciferase activity. In each case, a similar concentration
dependence was seen for inhibition, although the infection
assay was slightly less sensitive than the fusion assay at high
concentrations of the anti-CCR5 antibody (2D7, Fig. 4a).
Similar assays were carried out with two different preparations
of T-20, a TM-fusion inhibitor, and inhibitory concentrations
identified in the fusion assay were similar to those reported
previously using infection assays (Fig. 4b) (Derdeyn et al.,
2001).
Identification of a Rac GEF inhibitor that blocks HIV entry
The virus-dependent fusion assay was utilized to identify
novel HIVentry inhibitors. Based on previous observations of a
role of Rac activation during HIV fusion, we examined aninhibitor of the Rac-1 GEFs, Trio and Tiam, NSC23766 (Gao et
al., 2004). This drug blocked HIV fusion, as measured by the
Env-dependent fusion assay (Figs. 5a, b), infection (Fig. 5c), or
virus-dependent fusion (Fig. 5d). The concentration range of
HIV inhibitory activity was similar to that required to block
Rac-1 activation (not shown). No effects of Rac GEF inhibitor
were seen on Rho activation resulting from HIV Env-mediated
fusion (not shown).
In order to examine the specificity of the effects of the Rac
GEF inhibitor, a constitutively active Rac mutant, RacV12, was
used to overcome the inhibitor effects by activating the signaling
pathway downstream of the Rac GEFs. RacV12 overcame the
Fig. 5. Dose-dependent inhibition of R5-Env-dependent fusion or infection of
U87.CD4.CCR5 cells using a Rac GEF inhibitor. (a) Rac GEF inhibitor was
added at the time of cell mixing or (b) target U87 and/or HIV-1 ADA Env-
expressing BSC40 cells were pretreated for 1 h, washed, and mixed prior to
measuring fusion activity by β-galactosidase activity. (c) Cells were infected
with 10 ng p24 of HIVluc derived from HIV-1 ADA, with drug added at the time
of virus addition. Luciferase activity was determined 16 h post-infection,
expressed as relative light units (RLU). (d) Rac GEF inhibitor was added at the
time of virus in a virus-dependent fusion assay. Experiments were repeated 3
times, and representative data shown.
Fig. 6. Constitutively active RacV12 overcomes the effects of the Rac GEF
inhibitor. (a) Effects of RacV12 on the ability of the Rac GEF inhibitor to block
the ability of HIVADA mediated fusion to activate Rac activation, as measured
by the level of Rac-GTP in the cells. (b) Effects of RacV12 on the ability of the
Rac GEF inhibitor to block HIV-1 ADA Env-dependent fusion.
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GTP in cell lysates resulting from HIV Env-mediated fusion
(Fig. 6a). Moreover, RacV12 overcame the effects on Env-
mediated fusion of the Rac GEF inhibitor (Fig. 6b).
Conclusions
The virus-dependent fusion assay provides a rapid, sensitive,
flexible method to examine the biological activity of laboratory
or natural isolates of HIV-1, -2, or SIV and may have
applications to many other viruses that mediate pH-independentfusion. It compares favorably with other assays of virus, such as
one that depends upon transfer of a virus core containing a Vpr-
β-lactamase fusion protein into a target cell, which requires a
longer incubation time and FACS analyses (Cavrois et al., 2004;
Cavrois et al., 2002). It is likely that the virus-dependent fusion
assay can also examine pseudotyped HIV particles to identify
inhibitors of other viral glycoproteins, as shown with the β-
lactamase assay (Yonezawa et al., 2005). This assay has
advantages over various env-dependent fusion assays since it
utilizes relevant levels of virus-associated glycoprotein and does
not require multiple receptor contacts for initiating the activity
(Saeed et al., 2006).
The rapidity of the virus-dependent assay is ideal for
screening panels of potential HIVentry inhibitors and is readily
adaptable for high throughput screens. The assay is effective at
identifying inhibitory small molecules and antibodies. It may
have applications for studies of neutralizing antibodies directed
against HIV-1. Lastly, differences in results of virus-dependent
fusion and infection assays may provide new insights into
biological differences between different virus isolates.
Rac activation is critical in other aspects of HIV biology
besides entry. HIV-1 Nef binds the DOCK–ELMO complex
and p21-activated kinase 2 complex to initiate Rac activation,
inhibit lymphocyte chemotaxis, and induce merlin phosphor-
ylation (Janardhan et al., 2004; Lakhe-Reddy et al., 2006). Rac
activation is also important for other viruses. Rho and Cdc42
mediate adenovirus endocytosis (Li et al., 1998). Early steps in
herpes simplex virus type 1 infection are dependent upon
regulated Rac and Cdc42 signaling (Hoppe et al., 2006). In
contrast, Rho activation facilitates Kaposi's sarcoma herpes-
virus entry (Veettil et al., 2006).
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further substantiates the role of Rac activation in the fusion
process. Additional studies of downstream mediators of Rac
activity in HIV fusion have shown no effects of chemical
inhibitors of NADPH oxidase, MEK, PI-3 kinase, or myosin
light chain kinase, or dominant-negative inhibitors of Pak-2 or
PI-3 kinase (our unpublished findings). It is quite possible that
Rac activation through the WAVE, Arp 2/3 complex is
important for HIV fusion. Further studies of the entire signaling
pathway involved in HIV fusion should be informative in
developing new strategies to block infection.
Materials and methods
Inhibitors
The CCR5 and CD4 monoclonal antibodies 2D7 and Sim.2,
and T-20 drugs were obtained through the AIDS Research and
Reference Reagent Program, Division of AIDS, National
Institute of Allergy and Infectious Diseases (Derdeyn et al.,
2001; Pravecz and Norcross, 1993; Wu et al., 1997).
Viruses
Recombinant vaccinia viruses expressing β-galactosidase
(vCB21R), T7 polymerase (vPT7-3), and CD4 (vCB-3) were
obtained from the AIDS Research and Reference Reagent
Program, vaccinia viruses encoding an uncleaved HIVenvelope
(UNC; vCB-16), ADA envelope (vCB-39), and HXB2 envelope
(vSC60) as well as wild type vaccinia virus (vWT) were gifts
from Dr E Berger, vaccinia viruses encoding the YU2 envelope
(vSP-5) and constitutively active Rac GTPase (vRacV12) were
gifts from Drs C Broder and S Wei, respectively. HIV virus
stocks were prepared by lipofection of plasmid DNA encoding
full-length proviral molecular clones, with the Env gene of the
R5 YU2, ADA, or SF162 strains or the X4 HXB2 strain in the
HIV NL4-3 backbone (Pontow and Ratner, 2001; Pontow et al.,
2004), or with a mutation in the Gag gene at residue 12 (L12E;
our unpublished data). HIV Luc viruses encode the firefly
luciferase gene in place of Nef. Transfected 293T cell super-
natants were harvested after 48 h, filtered, and titered for p24
antigen content by ELISA. Twenty-seven low-passage isolates
obtained at serial visits from participants in the Baltimore site of
the Multicenter AIDS Cohort Study (MACS) are also included
(Kaslow et al., 1987).
Fusion and infection assays
The HIV-1 envelope-mediated fusion assay was modified
from that developed by Dr Berger (Nussbaum et al., 1994). The
U87 cell lines were serum-starved for 36 h then infected
overnight at 37 °C with vCB21R at MOI=10, and in some cases
recombinant vaccinia virus encoding the constitutively active
GTPase RacV12 mutant (vRacV12). Fusion partner BSC40
cells were infected overnight with vPT7-3 and vCB-39 encoding
the ADA envelope. Alternatively, in some experiments 106
BSC40 cells were transfected with 5–10 μg of proviral plasmidsand infected after 1 h with vPT7-3. Cells were then lightly
trypsinized, washed, and incubated with or without the Rac GEF
inhibitor for 1 h at 37 °C. Cells (105) of each type are then mixed
1:1 in triplicate wells, incubated for 3 h at 37 °C, and fusion
stopped by the addition of NP-40 to a final concentration of 1%
and freeze thawing at −20 °C. β-galactosidase activity was
determined using chlorophenol red-β-D-galactopyoranoside
(CPRG, Calbiochem) and the absorbance of each sample
determined at 579 nm (Pontow et al., 2004).
The virus-dependent fusion assay was performed with free
virus particles obtained 48 h after transfection of 293T cells
(Pontow et al., 2004). Virus was incubated in the presence of
20μg/mlDEAE-dextranwith 105 U87.CD4.CCR5 cells infected
for 18 h with vPT7-3 and 105 U87.CD4.CCR5 cells infected for
18 h with vCB21R. Assays were performed in triplicate wells.
Fusion activity was quantified as described above.
Infection assays were performed with Magi.CD4 or Magi.
CD4.CCR5 cells and number of blue foci determined days post-
infection (Pirounaki et al., 2000). Alternatively, for some assays,
viruses with luciferase expressed in place of Nef were utilized,
and luciferase activity measured 1–2 days after infection.
Rac and Rho activation assays
These assays were performed with 2×106 serum-starved
U87.CD4.CCR5 cell mixed at a ratio of 1:1 with BSC40 cells
infected with vaccinia virus expressing Env or vWT. In some
cases, one population of U87.CD4.CCR5 cells was infected
with vRacV12. Rac GEF inhibitor was added at the indicated
concentrations to the target cells 1 h prior to mixing and again at
the time of mixing. Reactions were incubated at 37 °C for
30 min, washed two times with ice cold PBS, and cells lysed.
Lysates were snap frozen and later equal amounts of protein per
well were analyzed using a G-LISA Rac activation or Rho-A
activation assay kit according to the manufacturer's instructions
(Cytoskeleton, Denver, CO).
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